drugset / Trial / NCT03121313

Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+

NCT03121313

Phase 2 Unknown 68 enrolled Chang Gung Memorial Hospital
NaSingle-groupOpen-labelTreatment

Summary

Primary Objective: To determine the 2-year distant failure rate of maintenance tegafur-uracil in patients with squamous cell carcinoma of oral cavity with extracapsular spreading of lymph nodes. Secondary Objectives: * To determine the 2-year locoregional failure rate. * To evaluate the 2-year overall survival (OS) rate. * To evaluate the 2-year progression-free survival (PFS) rate. * To assess the safety profiles.

Timeline

Start
2015-02-26
Primary completion
2020-05-11
Completion
2020-05-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject tegafur-uracil Small molecule 300 mg
Subject tegafur-uracil Small molecule 400 mg